Last reviewed · How we verify

OKITASK® — Competitive Intelligence Brief

OKITASK® (OKITASK®) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Ophthalmic anti-inflammatory/corneal healing agent. Area: Ophthalmology.

phase 3 Ophthalmic anti-inflammatory/corneal healing agent Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

OKITASK® (OKITASK®) — Dompé Farmaceutici S.p.A. OKITASK is a topical ophthalmic agent designed to promote corneal healing and reduce inflammation in dry eye disease.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
OKITASK® TARGET OKITASK® Dompé Farmaceutici S.p.A phase 3 Ophthalmic anti-inflammatory/corneal healing agent

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Ophthalmic anti-inflammatory/corneal healing agent class)

  1. Dompé Farmaceutici S.p.A · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). OKITASK® — Competitive Intelligence Brief. https://druglandscape.com/ci/okitask. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: